Related Experiment Video
Updated: Jun 12, 2026
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Targeting Adipocyte Enhancer-Binding Protein 1 to Induce Microglial Phenotype Shift for Immunotherapy in Alzheimer's
Eun-Ji Kim1, Byeong-Hyeon Kim2, Ye-Bin Mun1
1Department of Biomedical Laboratory Science, Konyang University, Daejeon 35365, Republic of Korea.
Abstract:
Neuroinflammation, a key contributor to neurodegenerative diseases, results from excessive microglial activation. Microglia that respond to pathogenic molecules switch to the M1 type and secrete various immune cytokines, which can cause neuronal damage. Therefore, our study focused on molecules that can enhance the neuroprotective role of microglia and reduce neuronal damage. The adipocyte enhancer-binding protein 1 (AEBP1) gene is known for its role in regulating immune responses in macrophages. However, its role in neuroinflammation has not been fully explored. Therefore, we investigated the role of AEBP1 in microglial cells activated by lipopolysaccharide (LPS). First, we confirmed that AEBP1 is expressed in LPS-activated microglia and demonstrated that downregulation of AEBP1 using shRNA in activated microglia reduced the immune response via the nuclear factor-kappa-B (NFκB) pathway. These results promote a shift toward neuroprotective M2 microglia, thereby reducing neuronal damage. Next, we confirmed that the expression of AEBP1 was elevated in the brains of Alzheimer's disease (AD) mice. Additionally, animal experiments to assess the therapeutic effects of AEBP1 showed that microglia gathered around amyloid beta (Aβ) and reduced its size. Taken together, our results provide the first evidence that AEBP1 can reduce inflammatory activity in microglia, suggesting its potential as a target molecule for immunotherapy.
Insights
Adipocyte enhancer-binding protein 1 (AEBP1) reduces neuroinflammation by decreasing immune responses in microglia. This shift promotes neuroprotection and lessens neuronal damage, offering potential for Alzheimer's disease immunotherapy.
Area of Science:
- Neuroscience
- Immunology
- Molecular Biology
Background:
- Neuroinflammation, driven by excessive microglial activation, contributes significantly to neurodegenerative diseases.
- Activated microglia (M1 type) secrete immune cytokines, leading to neuronal damage.
- The role of adipocyte enhancer-binding protein 1 (AEBP1) in neuroinflammation remains largely unexplored.
Purpose of the Study:
- To investigate the role of AEBP1 in microglial cells activated by lipopolysaccharide (LPS).
- To explore AEBP1's potential as a therapeutic target for neurodegenerative conditions.
Main Methods:
- Investigated AEBP1 expression in LPS-activated microglia.
- Utilized shRNA to downregulate AEBP1 in activated microglia.
- Examined the effect of AEBP1 on the nuclear factor-kappa-B (NFκB) pathway.
- Assessed AEBP1 expression in Alzheimer's disease (AD) mouse models.
- Evaluated therapeutic effects of AEBP1 in animal models.
Main Results:
- AEBP1 expression was confirmed in LPS-activated microglia.
- Downregulation of AEBP1 reduced the immune response via the NFκB pathway.
- AEBP1 downregulation promoted a shift towards neuroprotective M2 microglia.
- Elevated AEBP1 expression was observed in the brains of AD mice.
- AEBP1 administration led to microglial aggregation around amyloid-beta (Aβ) plaques and reduced plaque size.
Conclusions:
- AEBP1 plays a crucial role in regulating microglial inflammatory responses.
- AEBP1 can reduce inflammatory activity in microglia, shifting them to a neuroprotective phenotype.
- AEBP1 shows potential as a therapeutic target for neuroinflammation and Alzheimer's disease immunotherapy.
